Onco Wiki / Maladie

Glioblastoma (IDH-WT, WHO grade 4)

Vue déterministe de l'entité source de la LJAM. L'autorité clinique demeure avec les ID de la source cités et l'état d'approbation de l ́examinateur.

IDDIS-GBM
TypeMaladie
Alias
GBMGlioblastomeGlioblastome multiforme (terme d'héritage)Гліобластома (IDH-WT, WHO grade 4)
Étatreviewed 2026-04-26 | pending_clinical_signoff
MaladiesAucune déclaration
SourcesSRC-EANO-GBM-2024 SRC-NCCN-CNS-2025

Informational support. All recommendations must be verified by a qualified oncologist. Engineering checks are not clinical validation or treatment approval.

Source YAML

icd_o_3_morphology9440/3
icd_o_3_topography["C71"]
icd_10C71
who_classificationWHO CNS Tumours 5th ed (2021): Glioblastoma, IDH-wildtype, grade 4 (the IDH-mutant grade-4 astrocytoma is a distinct entity)

Capacités

Notes

Scaffolded for batch #2: 4 RFs (intracranial-pressure emergency, MGMT-actionability, frailty/age — elderly Stupp-modified, biopsy-only vs maximal-safe-resection MDT-trigger). 1 regimen (TMZ Stupp concurrent + adjuvant). 2 indications (Stupp full for fit; TMZ-only for elderly unmethylated unfit). 1 algorithm. Lineage value `carcinoma` is suboptimal — neuroepithelial would be more accurate. Schema's lineage field is free-text Optional; using `carcinoma` for now to match other solid-tumor entries; clinical authors may want to add `glioma` / `neuroepithelial` enum value in future. RT 60 Gy / 30 fractions concurrent with TMZ 75 mg/m²/d daily during RT is the canonical Stupp concurrent phase. RT NOT modellable per PROPOSAL §17 — treated as free-text in Indication.notes for now.

Utilisé par

Pertinence thérapeutique

Algorithmes

Maladie

Indication

Questionnaires

Signal d’alerte

Sources